Forecast

The analysts' average price target is €38.80 (+15.72%). The median is €38.58 (+15.06%).

Buy	21
Hold	21
Sell	4

News Go to news feed

Teva accelerates pivot to growth as branded drugs and biosimilars drive outlook

Teva says its 'Pivot to Growth' strategy is entering a faster phase as branded medicines gain momentum, generics stabilize and biosimilars expand. Management highlighted AUSTEDO's potential to exceed $3 billion, AJOVY approaching $1 billion, and UZEDY plus long‑acting olanzapine representing a $1.5–2 billion opportunity. The company has 11 biosimilars on the market with about nine more planned by decade-end and expects to beat its $800 million biosimilars target for 2027 early. Teva also reduced debt, secured investment‑grade ratings ahead of schedule, completed refinancing, and is advancing pipeline assets including ecopipam and duvakitug toward potential 2027 launches. » More on finance.yahoo.com
S&P upgrades Teva to BBB- after debt reduction and strong branded pipeline

S&P Global Ratings has upgraded Teva from BB+ to BBB- and raised all of the company’s ratings. The agency cites ongoing debt reduction, stabilization in the generics business and growth of high-margin branded products; leverage is expected to fall from about 4x in the second quarter to the mid-3x range by year-end. S&P expects strong adjusted operating cash flow of $2.3–2.5 billion annually, substantial cost savings through 2027, as well as revenue gains from key brands such as Austedo, Ajovy and Uzedy and important product launches in the coming years. » More on de.investing.com
Teva asks judge to bar mention of Israeli origin at Humana price-fixing trial

Teva asked a U.S. judge to prevent insurer Humana from telling jurors the company is Israeli, arguing references to its national origin could prejudice the jury amid strong U.S. emotions over the Gaza war. The Tel Aviv-based drugmaker said national origin is irrelevant to allegations it conspired to inflate generic drug prices and could undermine a fair trial. The U.S. trial is scheduled to begin Sept. 15 and covers claims over drugs including baclofen and propranolol. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics

In 2017, Teva Pharmaceuticals has already paid €0.66 in dividends. The last payout was in December 2017.

Financials

In the last quarter, Teva Pharmaceuticals had revenue of €3.63bn and net profit of -€504.7m

(EUR)	June 2026	YoY
Revenue	3.63bn	2.43%
Gross profit	1.89bn	5.78%
Net profit	-504.7m	310.95%
EBITDA	-16.65m	102.99%

Fundamentals

Metric	Value
Market capitalization	€37.45bn
Number of shares	1.16bn
52-week high/low	€33.26 - €15.79
Dividends	No
Beta	0.87
P/E ratio	58.25
PEG ratio	0.11
P/B ratio	5.51
P/S ratio	2.46

Company profile

Teva Pharmaceutical Industries Limited, ein Pharmaunternehmen, entwickelt, produziert, vermarktet und vertreibt Generika, Spezialmedikamente und biopharmazeutische Produkte in Nordamerika, Europa und international. Das Unternehmen bietet sterile Produkte, Hormone, hochwirksame Medikamente und zytotoxische Substanzen in verschiedenen Darreichungsformen an, darunter Tabletten, Kapseln, Injektionsmittel, Inhalationsmittel, Flüssigkeiten, transdermale Pflaster, Salben und Cremes. Außerdem entwickelt, produziert und vertreibt das Unternehmen pharmazeutische Wirkstoffe. Darüber hinaus konzentriert sich das Unternehmen auf die Bereiche zentrales Nervensystem, Schmerzen, Atemwege und Onkologie. Zu den Produkten im Bereich des zentralen Nervensystems gehören Copaxone zur Behandlung schubförmiger Formen der Multiplen Sklerose, AJOVY zur vorbeugenden Behandlung von Migräne und AUSTEDO zur Behandlung von Spätdyskinesien und Chorea im Zusammenhang mit der Huntington-Krankheit. Die Produkte des Unternehmens auf dem Atemwegsmarkt umfassen ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler und ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax und AirDuo RespiClick/ArmonAir RespiClick für die Behandlung von Asthma und chronisch obstruktiven Lungenerkrankungen. Zu seinen Produkten auf dem Onkologiemarkt gehören Bendeka, Treanda, Granix, Trisenox, Lonquex und Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited kooperiert mit MedinCell bei der Entwicklung und Vermarktung mehrerer langwirksamer injizierbarer Produkte, einer Risperidon-Suspension für die Behandlung von Patienten mit Schizophrenie. Das Unternehmen wurde 1901 gegründet und hat seinen Hauptsitz in Tel Aviv-Yafo, Israel.

Name	Teva Pharmaceuticals
CEO	Richard D. Francis
Headquarters	Tel Aviv, ta USA
Website	tevapharm.com
Sector	Health Care
Industry	Pharmaceuticals
IPO	16/02/1982
Employees	32,008